As this is an explorative design, no formal hypothesis is made. However, our sample size is based on a difference of 2.5% or more in cumulative incidence of serious infections when continuing IA, hypothesizing that patients who continue their IA in…
ID
Bron
Verkorte titel
Aandoening
- Auto-immuunziekten
Aandoening
Rheumatoid arthritis
Psoriatic arthritis
Axial spondyloarthritis
Immune mediated inflammatory diseases
Inflammatory rheumatic diseases
Betreft onderzoek met
Ondersteuning
Onderzoeksproduct en/of interventie
- Overige
Uitkomstmaten
Primaire uitkomstmaten
Achtergrond van het onderzoek
Immunomodulatory agents (IA) are widely used (>200,000 patients in the Netherlands) for the treatment of patients with immune-mediated inflammatory diseases (IMIDs) including rheumatoid arthritis, psoriatic arthritis, axial spondylarthritis, psoriasis and inflammatory bowel disease, and they are in general associated with a modestly increased risk of infection. However, it is not clear what risk factors for infection are, and whether it is wise to temporary interrupt IA treatment during an infection. Recently, the COVID-19 pandemic has dramatically increased the urgency to provide answers to these questions, especially since, surprisingly, some IA seem to be effective treatment against COVID-19. Therefore, the objectives of this study are to: 1) To assess the effect of continuation of IA treatment in IMID patients during an infection compared to temporary interruption of the IA treatment with regard to serious infection, and 2) to study the incidence and risk factors for infection in IMID patients using IA, with special attention for COVID-19. This study is a two arm, open-label pragmatic, explorative randomized controlled strategy study, among IMID patients using IA in the Netherlands. Adult patients with rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, psoriasis and inflammatory bowel disease using IA (except monotherapy rituximab or glucocorticoids) in any dose without a current infection will be included and randomized into either the intervention or control group. The intervention consists of continued IA treatment and the control condition is interruption of IA treatment until the infection is resolved, all in addition to standard of care. Main study parameters/endpoints: The primary outcome is serious infection (resulting in hospitalization, intravenous antibiotics, admission to the intensive care or death)
Doel van het onderzoek
As this is an explorative design, no formal hypothesis is made. However, our sample size is based on a difference of 2.5% or more in cumulative incidence of serious infections when continuing IA, hypothesizing that patients who continue their IA in case of an infection experience less severe infections compared to patient who temporarily interrupt IA.
Onderzoeksopzet
Patients will be followed for 12 months, receiving questionnaires at baseline and one each following month. If a patient experiences an infection at t = 12 months, he/she will be followed until the infection has passed. In addition, data will be collected in case of an infection.
Onderzoeksproduct en/of interventie
Publiek
Wetenschappelijk
Leeftijd
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
- Clinical diagnosis of at least one of the following IMIDs: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), psoriasis (PsO) or inflammatory bowel disease (IBD) (i.e. Crohns disease (CD) or ulcerative colitis (UC). - Age ≥ 16 years - Using one or more of the following immunomodulating agents (IA) from table 1 in any dose. Monotherapy rituximab and glucocorticoids are exempts because rituximab cannot be stopped due to long half-life time and post pharmacokinetic effects on b-cell depletion, and glucocorticoids because stopping is associated with secondary hypocortisolism. - Not experiencing any clinical infection at time of inclusion (based on check in electronic health record and as reported by patient at inclusion). - Ability to read and communicate well in Dutch
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
- Use of the following immunomodulating agents in monotherapy and through intravenous administration: rituximab, tocilizumab or abatacept. This because the contrast between stopping and continuation is expected to be low, as the treatment intervals are high, and intravenous medication is not easily provided in case of hospital admission. - Use of glucocorticoids (GC) in monotherapy, because stopping of GC is not feasible due to risk of GC use induced hypocortisolism - Not willing to be randomized to either intervention or control condition. - Not being able to be followed for 12 months, because of planned relocation or short life expectancy.
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Toelichting
p/a Radboudumc, huispost 628,
Postbus 9101
6500 HB Nijmegen
024 361 3154
commissiemensgebondenonderzoek@radboudumc.nl
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL8922 |
CCMO | NL73479.091.20 |
OMON | NL-OMON54899 |